# First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial

> **NCT06922279** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 108 (estimated)

## Conditions studied

- Gastroesophageal Cancer (GC)

## Interventions

- **RADIATION:** Radiation Therapy + standard sistemic therapy (chemoteraphy)
- **DRUG:** Standard systemic therapy (chemotherapy)

## Key facts

- **NCT ID:** NCT06922279
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-30
- **Primary completion:** 2029-10-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06922279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06922279, "First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06922279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*